Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1641
This examiner grants 55% of resolved cases
Micah Paul Young has resolved 983 cases in Art Unit 1618 within Tech Center 1600. The examiner's allowance rate is 55.1%, which is just above half of all resolved cases. The median days to allowance is 1325, indicating a standard duration for prosecution. This large dataset of 983 cases provides a reliable view of the examiner's typical outcomes and timelines.
The interview lift is 30.0%, indicating that interviews are a productive tool. This 30.0% lift suggests that the probability of allowance increases significantly when practitioners speak directly with the examiner. Given the 55.1% allowance rate, an interview could be the deciding factor in many cases. The 1325 days median pendency also suggests that early interviews might help in resolving issues more quickly, potentially improving the 55.1% success rate for those who choose to engage verbally in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18103932 | IODINATED COMPOUNDS AND HYDROGELS FORMED FROM SAME | Final Rejection | Boston Scientific Scimed, Inc. |
| 19051618 | COMPOSITIONS HAVING ENHANCED DEPOSITION OF SURFACTANT-SOLUBLE ANTI-DANDRUFF AGENTS | Non-Final OA | The Procter & Gamble Company |
| 19030494 | LIMIT SIZE LIPID NANOPARTICLES AND RELATED METHODS | Non-Final OA | The University of British Columbia |
| 18249663 | MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING ANTITUMOR T CELL IMMUNITY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 19064586 | WOUND DRESSINGS | Non-Final OA | ConvaTec Limited |
| 18011071 | NON-INTUITIVE COMBINATION OF DRUG DELIVERY CARRIERS OF THE SAME DRUG FOR SYNERGISTIC GROWTH DELAY OF SOLID TUMORS | Final Rejection | The Johns Hopkins University |
| 17737229 | INTRANASAL ADMINISTRATION OF GLUTAMATE CARBOXYPEPTIDASE (GCP-II) INHIBITORS | Non-Final OA | The Johns Hopkins University |
| 17611929 | RADIOTHERAPEUTIC MICROSPHERES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | Non-Final OA | Novartis AG |
| 19065875 | METHOD OF CONTROLLING WEEDS | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18612007 | Carrier Systems For Cannabinoids | Final Rejection | Fertin Pharma A/S |
| 19023669 | COMPOSITIONS COMPRISING ATICAPRANT | Non-Final OA | Janssen Pharmaceuticals, Inc. |
| 17789343 | Pharmaceutical Composition of CASR Modulators and Methods and Uses Thereof | Final Rejection | Lupin Limited |
| 17790830 | Methods of Determining Impaired Glucose Tolerance | Non-Final OA | Somalogic Operating Co., Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy